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1. INTRODUCTION 
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) provides 
the only curative treatment for many conditions including malignancies, 
hereditary and immune-mediated diseases. Worldwide there has been a 
linear increase in allo-HSCT activity. Estimations suggest that the one 
millionth HSCT (considering both autologous and allogeneic forms) in the 
world has been performed by the end of 2012. According to the most recent 
European Society for Blood and Marrow Transplantation (EBMT) survey 
the number of allogeneic transplants performed yearly in the more developed 
European countries is in the range of 201-300 per 10 million population. 
Although the outcome of patients undergoing the treatment has been 
gradually improving, allo-HSCT remains a high risk procedure with 
significant transplant-related mortality. The success of allo-HSCT in 
malignant disorders heavily relies on the beneficial post-transplant graft-
versus-leukaemia/tumour effect that potently eradicates malignant cells. At 
the same time, the immunological attack delivered by donor cells on target 
recipient tissues can result in acute graft-versus-host disease (aGvHD). 
Acute GvHD is the leading cause of non-relapse mortality post-transplant 
and as such is the major impediment of allo-HSCT. Acute GvHD resembles 
an acute inflammatory reaction manifesting in the clinical picture of skin 
rash, nausea, vomiting, diarrhoea and liver dysfunction. Despite many novel 
modalities the outcome of aGvHD has not improved greatly. Extensive 
research efforts have been generated to predict and prevent the development 
of aGvHD. Numerous risk factors have been identified, and the ones that 
could potentially impact on donor selection preferences are of high 
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importance. With regards to genetic risk factors human leucocyte antigen 
(HLA) disparity between the recipient and the donor is the most relevant. On 
the other hand, high-resolution HLA matching cannot prevent the 
development of aGvHD, highlighting the involvement of other genetic 
systems. The discovery of genetic pathways involved in alloimmune 
reactions is of high significance that could help the prevention of 
complications via better donor selection and by shaping future drug 
development. Cytokines play an essential role in aGvHD reactions. Many of 
the cytokines with relevance for aGvHD relay their signals via the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) 
pathway. Our hypothesis was that polymorphisms of the pathway, including 
Janus kinase 2 (JAK2) might affect the manifestation of aGvHD.  Among 
JAK2 variants, the investigation of 46/1 haplotype seemed to be relevant as 
it has been reported to have functional consequences. Transplantation-
associated thrombotic microangiopathy (TA-TMA) is another, feared 
complication of allo-HSCT due to its dismal prognosis (median mortality 
75%). The key element of TA-TMA is endothelial dysfunction induced by 
various triggers such as infections, drugs or aGvHD. The clinical course 
presents with microangiopathic haemolytic anaemia, thrombocytopenia and 
organ dysfunction secondary to microthrombi with predilection in the 
kidneys. Giving the poor outcome of TA-TMA, the identification of risk 
factors and measures to prevent its development are of high clinical 
significance. HLA-DRB1*11 shows strong association with thrombotic 
thrombocytopenic purpura (TTP), another form of TMA. Giving the 
similarities of the clinical presentation of TTP and TA-TMA, we 
hypothesised that HLA-DRB1*11 could also be associated with TA-TMA.     
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2. OBJECTIVES 
2.1. Establishment of database  
The primary aim of our work was to set up a database including detailed 
patient-, donor-, and transplantation-related characteristics and outcome data 
of all first allogeneic haematopoietic stem cell transplantations performed in 
adult patients (n=425) for haematological malignancies in Hungary between 
2007 and 2013.  
Data were assembled for the following parameters; 
a) Patient-, and disease-associated characteristics:  
Patient age, gender, diagnosis, stage of disease, ABO and Rh blood groups, 
CMV serostatus, HLA type, karyotypic abnormalities in acute leukaemia;  
b) Donor-specific features: 
Related vs. unrelated donor type, donor sex, ABO and Rh blood groups, 
CMV serostatus, HLA type; 
c) Transplantation-related characteristics: date of transplant, conditioning 
intensity and type, stem cell source, applied GvHD prophylactic regimen; 
d) Outcome data: engraftment, relapse rate and timing, incidence, timing and 
severity of TA-TMA, aGvHD and CMV reactivation, overall survival, cause 
of death. 
 
2.2. Transplantation-associated thrombotic microangiopathy (TA-
TMA) study 
This work aimed at addressing the following questions in association with 
TA-TMA development; 
 What is the incidence and timing of TA-TMA? 
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 What proportion of patients develop organ damage? 
 What are the risk factors for TA-TMA? 
 Does HLA-DRB1*11 show an association with TA-TMA? 
 Does the development of TA-TMA affect the survival? 
 Does the prognosis differ in HLA-DRB1*11 carriers and non-
carriers?  
 
2.3. JAK2 46/1 haplotype study 
Our second study assessed the association of recipient and donor Janus 
kinase 2 (JAK2) 46/1 haplotypes with transplantation outcome. 
The following hypotheses were investigated; 
 Are recipient and donor JAK2 46/1 haplotypes associated with 
aGvHD grades II-IV. development? 
 Does the recipient/donor genotype combination affect the risk? 
 Do the recipient and donor JAK2 46/1 haplotypes correlate with 
relapse?  
 Are recipient and donor JAK2 46/1 haplotypes associated with 
survival?  
 
3. METHODS 
3.1. Patients 
The entire cohort consisted of 425 consecutive adult patients who underwent 
first allo-HSCT between January 2007 and December 2013 for a 
haematological malignancy at the Department of Haematology and Stem 
Cell Transplantation, St Istvan and St Laszlo Hospital, Hungary. Giving that 
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this hospital was the only centre delivering this treatment modality at the 
time, all transplants performed on adults in Hungary were included. The 
indications of HSCT were the following; acute myeloid leukaemia (n=157), 
acute lymphoid leukaemia (n=75), non-Hodgkin lymphoma (n=42), 
myelodysplastic syndrome (n=35), chronic lymphocytic leukaemia (n=26), 
multiple myeloma (n=25), chronic myeloid leukaemia (n=24), 
myeloproliferative neoplasm (n=23) and Hodgkin lymphoma (n=18). 
Related and unrelated donor sources were close to equal (51.1% related and 
48.9% unrelated). The majority of patients were treated with myeloablative 
conditioning (62.8%). GvHD prophylactic regimens were either 
cyclosporine (24%) or tacrolimus-based (76%). Our first study on TA-TMA 
was conducted in the whole cohort, whereas the second study on JAK2 46/1 
haplotype included patients (n=124) transplanted for acute myeloid 
leukaemia (AML) in complete remission (CR).  
 
3.2. Diagnosis of TA-TMA and acute GvHD 
The definition for TA-TMA diagnosis was based on overall TMA criteria 
including probable TMA cases without organ damage proposed by Cho et 
al.: 1.) Normal coagulation assays; 2.) ≥ two schistocytes per high power 
field; 3.) Increased lactate dehydrogenase; 4.) Negative Coombs test; 5.) De 
novo, prolonged or progressive thrombocytopenia (< 50x109/l or 50% or 
greater reduction from previous counts); 6.) Decrease in haemoglobin 
concentration; 7.) Decrease in serum haptoglobin. Patients with renal and/or 
neurological dysfunction (as defined by the Blood and Marrow Transplant 
Clinical Trials Network Toxicity Committee Consensus recommendations) 
were categorised as having TA-TMA with organ involvement.  
6 
 
Acute GvHD was defined and graded according to consensus criteria 
(modified Glucksberg). 
 
3.3. Detection of JAK2 46/1 haplotype 
For identification of JAK2 46/1 haplotype we tested SNP rs12343867, a 
fully-linked, tagging SNP to the haplotype. JAK2 rs12343867_C tags 46/1 
haplotype: the nucleotide C represents the haplotype, while T determines 
non-46/1 haplotype. Melting curve analysis with hybridization probe 
detection format on LightCycler 480II (Roche Diagnostics) was performed 
to identify the alleles of rs12343867.  
3.4. Statistical analysis 
The statistical analyses were performed by SPSS Statistics software version 
22 and STATA10 software. Categorical variables were compared using Chi-
square or Fisher’s exact tests, while continuous variables were tested by 
Mann-Whitney or Kruskal-Wallis tests. To assess associations of multiple 
factors with the outcome multivariate logistic regression was performed. 
Cumulative incidence was calculated by the Fine and Gray model. Survival 
between subgroups were compared by the log-rank test and estimated by the 
Kaplan-Meier method. Cox regression analysis was applied for the study of 
covariates in association with survival, hazard ratio (HR) and 95% 
confidence interval (95%CI) were calculated. All analyses were two-sided. 
P values of less than 0.05 were considered statistically significant, while p 
values between 0.05 and 0.1 were referred to as tendency. 
 
4. RESULTS 
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4.1. TA-TMA STUDY 
4.1.1. Incidence and timing of TA-TMA 
TA-TMA was diagnosed in 18.8% of the patients (80/425), of whom half 
showed signs of organ damage (n=41, 51.3% of TA-TMA patients). The 
median time to TA-TMA manifestation from the day of transplant was 40 
days (range 6-1670 days) and in the vast majority of patients (81.3%) TA-
TMA presented within the first 100 days of transplantation.  
4.1.2. Risk factors for TA-TMA manifestation 
We validated the association of TA-TMA with several previously published 
risk factors. TA-TMA affected 27.4% of patients with an unrelated donor as 
opposed to only 10.6% in those with a sibling donor (p<0.001). TA-TMA 
was significantly more prevalent following the administration of 
myeloablative conditioning (MAC) (23.2% versus [vs.] 11.4% with reduced 
intensity conditioning [RIC], p=0.003). TA-TMA was diagnosed in 9.0% in 
the cyclosporine (CSA)-based aGvHD prophylactic subgroup, whereas the 
incidence increased with tacrolimus (TAC) administration (21.8%, 
p=0.003), irrespectively of the other agent given in combination with TAC. 
Among the 80 TA-TMA patients, 66 simultaneously presented with aGvHD 
during follow-up, and in 90.9% of these cases aGvHD preceded TA-TMA. 
While TA-TMA was rare in patients without aGvHD (7.8%), 34.9% and 
55.0% were diagnosed among those who had grade II-III or IV aGvHD, 
respectively. CMV reactivation/disease were also proved to be risk factors 
for TA-TMA (p=0.003). Our study however failed to show association with 
other, implicated factors, such as recipient’s age, gender, gender matching, 
diagnosis and ABO compatibility.   
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In addition to the above mentioned, documented risk factors, as a new finding 
the analyses confirmed that carriership for HLA-DRB1*11 was also 
significantly associated with the manifestation of TA-TMA. TA-TMA 
occurred in 24.8% of HLA-DRB1*11 positive vs. in 16.0% of HLA-
DRB1*11 negative patients (p=0.034). The cumulative incidence of TA-
TMA showed significant alteration according to HLA-DRB1*11 (p=0.026, 
Figure 1.).  
 
Figure 1. Cumulative incidence of TA-TMA in HLA-DRB1*11 carrier and non-
carrier patients. 
In multivariate analysis including the above parameters significantly 
associated in univariate testing the association of TA-TMA with donor type 
and grades II-IV aGvHD was independent, there was a tendency for 
association with CMV reactivation and HLA-DRB1*11, while conditioning 
intensity and type of GvHD prophylaxis failed to show independent 
association. 
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Separate analyses in sibling and unrelated transplants were performed due to 
uneven distribution of donor type among HLA-DRB1*11 carriers and non-
carriers. The analyses showed that HLA-DRB1*11 carriership was 
significantly associated with the emergence of TA-TMA in the sibling 
subgroup (17.8% [10/56] in HLA-DRB1*11 positive versus 8.1% [13/161] 
in HLA-DRB1*11 negative cases; p=0.047), but not in the unrelated donor 
subset (29.6% [24/81] in HLA-DRB1*11 positive versus 26.0% [33/127] in 
HLA-DRB1*11 negative cases; p=0.633). 
4.1.3. The influence of TA-TMA on post-transplant overall survival 
The overall survival (OS) of patients who developed TA-TMA was 
significantly worse compared to patients without the complication (36-
month OS: 27.4±5.3% vs. 55.3±2.9%, p<0.001). Within the TA-TMA group, 
the outcome of patients with organ damage was more unfavourable 
compared to individuals without organ involvement (p=0.025). The survival 
of patients without TA-TMA was significantly better compared to both 
subgroups, patients with TA-TMA without organ involvement (p=0.015) and 
with organ damage (p<0.001). The survival of patients not affected by TA-
TMA was not influenced by HLA-DRB1*11 status (p=0.778), but carriers 
of HLA-DRB1*11 displayed superior OS within the cohort suffering from 
TA-TMA (p=0.003).  
Cox regression analysis confirmed that TA-TMA was an independent 
adverse risk factor for overall survival (HR 1.9, 95% CI: 1.35-2.62). Among 
TA-TMA patients carriership of HLA-DRB1*11 was an independent 
predictor of better survival (HR: 0.46, 95% CI: 0.27-0.81, p=0.007). 
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4.2. JAK2 46/1 HAPLOTYPE STUDY 
4.2.1. Outcome according to patients’ JAK2 46/1 haplotype 
Among the 124 transplant recipients (AML in CR) included in this study, 64 
(51.6%) carried the TT, non-46/1 haplotype genotype, the number of 
heterozygous and homozygous carriers for the 46/1 haplotype was 49 
(39.5%) and 11 (8.9%), respectively. In 46/1 haplotype carriers (R1) we 
observed significantly more grades II-IV aGvHD compared with non-
carriers (R0). By 100 days post-transplant aGvHD grades II-IV was 
diagnosed in 41.7% of haplotype carriers as opposed to 18.8% of non-
carriers (p=0.008, Figure 2.).  
 
Figure 2. Incidence of aGvHD grades II-IV by 100 days was 41.7% in haplotype 
carriers (R1) in contrast to 18.8% in non-carriers (R0, p=0.008). 
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At 2 years the cumulative incidence of relapse was significantly lower in 
haplotype carriers (5.0%) in comparison with non-carriers (23.5%, p=0.008). 
Despite alterations in the causes of death and relapse rate according to the 
haplotype, OS was comparable in 46/1 haplotype carriers and non-carriers 
(2-year OS 69.2±6.1% in carriers vs. 60.7±6.7% in non-carriers, p=0.732). 
4.2.2. Outcome according to donors’ JAK2 46/1 haplotype 
Similarly to recipient haplotype, moderate and severe aGvHD were more 
common in patients transplanted with haplotype carrier donors compared 
with patients transplanted with non-carrier donors by day 100 (39.7% vs. 
21.2%, p=0.038). Relapse rates were comparable in patients transplanted 
from carrier and non-carrier donors (13.8% vs. 15.2%, p=1). The survival 
was not significantly different according to the donor haplotype, but there 
was a tendency for better OS among patients transplanted from non-46/1 
haplotype carriers as opposed to  haplotype carriers: 2-year OS 73.9±5.7 vs. 
56.0±6.9% (p=0.056). 
4.2.3. Outcome according to recipient/donor JAK2 46/1 haplotype 
combinations 
As we observed that both recipient and donor haplotypes showed association 
with aGvHD, we elucidated how their combinations influenced the risk. The 
analysis confirmed significantly higher aGvHD risk if both, the recipient and 
the donor (R1D1) were 46/1 haplotype carriers in comparison with the non-
carrier patient/donor (R0D0) constellation (OR=5.242, 95% CI=1.784-
15.404, p=0.003). There was intermediate risk if either the recipient (R1D0) 
or donor (R0D1) was a carrier (Figure 3.).  
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Figure 3. Incidence of aGvHD grades II-IV according to recipient/donor haplotype 
pairs. Incidences were 13.9% in the R0D0, 28.6% in the R0D1, 34.8% in the 
R1D0, and 45.9% in the R1D1 group (p=0.030). 
The 2-year OS rates were not statistically different in the four above 
described recipient-donor groups (69.0±7.6% [R0D0], 82.1±8.1% [R1D0], 
42.1±13.3% ([R0D1] and 61.1±8.2% ([R1D1], p=0.211).  
In univariate analyses, aGvHD grades II-IV were significantly associated 
with unrelated donor type (p=0.031), myeloablative conditioning (p=0.036), 
recipient age at transplantation (p=0.046), JAK2 46/1 haplotype in the 
recipient (p=0.006) and in the donor (p=0.031). Multivariate analyses 
confirmed that recipient JAK2 46/1 haplotype was independently associated 
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with aGVHD (p=0.012), whereas the donor haplotype was not, however 
there was a tendency (p=0.08). 
5. CONCLUSIONS 
1. Our work identified two novel risk factors for the development of 
serious post-transplant complications, transplantation-associated 
thrombotic microangiopathy and acute graft-versus-host disease in 
this single centre cohort of adult Hungarian patients undergoing 
allogeneic HSCT.  
2. TA-TMA was diagnosed in nearly the fifth (18.8%) of the patients 
with predominant presentation in the early post-transplant period 
(median 40 days, in 81% within first 100 days of transplantation). 
Organ damage was noted in 51.3% (41/80) of patients with TA-
TMA. Unrelated donor type, acute GvHD grades II-IV, 
myeloablative conditioning, tacrolimus-based immunosuppression, 
CMV reactivation/disease and as a novel finding carriership for 
HLA-DRB1*11 were the identified risk factors for TA-TMA 
development.  
3. TA-TMA was an independent adverse factor for overall survival. 
Within the TA-TMA group the presence of organ damage adversely 
affected the outcome, whereas the outcome was more favourable in 
HLA-DRB1*11 carriers.  
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4. In the AML cohort we confirmed as a new observation that both, 
recipient and donor JAK2 46/1 haplotypes were associated with the 
development of aGvHD grades II-IV. Moreover the impact of the 
recipient and donor genetic variant seemed to be cumulative giving 
that the highest incidence was disclosed among those, who 
themselves and their donors were both haplotype carriers. 
Multivariate analyses confirmed that the recipient JAK2 46/1 
haplotype was independently associated with aGVHD, however the 
donor JAK2 46/1 haplotype was not.  
5. Recipient JAK2 46/1 haplotype showed a favourable correlation 
with relapse rate, but the donor JAK2 46/1 haplotype had no effect 
on relapse incidence. The recipient and donor JAK2 46/1 haplotypes 
had no significant impact on post-transplant overall survival.  
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